Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome.
Ville VarhoTuomas O KiviniemiWail NammasJussi SiaHannu RomppanenMikko PietiläJuhani K AiraksinenJussi MikkelssonPetri TuomainenAnssi PeräläPasi P KarjalainenPublished in: The international journal of cardiovascular imaging (2016)
Data on early vascular healing response of novel stent designs are scarce. In this randomized prospective trial, we sought to compare early neointimal coverage of cobalt-chromium-based titanium-nitride-oxide-coated bioactive stents (CoCr-BAS) versus platinum-chromium everolimus-eluting stents (PtCr-EES) at 2-month follow-up in patients with acute coronary syndrome (ACS). Forty patients with ACS were randomized to receive either CoCr-BAS (n = 19) or PtCr-EES (n = 21). Neointimal strut coverage and strut apposition were examined by optical coherence tomography; and coronary flow reserve (CFR), fractional flow reserve (FFR) and index of microcirculatory resistance (IMR) were assessed using a coronary pressure wire at 2 months. Two patients in the PtCr-EES underwent OCT out of the time frame of the study, and were excluded from analysis. At 63 ± 8 days, 302 cross-sections (3412 struts) were analysed in the CoCr-BAS group, and 324 cross-sections (3460 struts) in the PtCr-EES group. Median [IQR] neointimal thickness was 203 [108] µm and 42.2 [41] µm for CoCr-BAS and PtCr-EES, respectively (p < 0.001). Median [IQR] percentage of uncovered struts was 1.2 [2.8] % versus 11.3 [17.7] %, respectively (p < 0.001). Flow measurements were comparable between the two groups (p > 0.05 for all). CoCr-BAS showed earlier and more adequate neointimal coverage of struts at 2 months, compared with PtCr-EES, but with more neointimal hyperplasia. Functional healing as assessed by CFR, FFR, and IMR was similar between the two stent arms.
Keyphrases
- vascular smooth muscle cells
- smooth muscle
- optical coherence tomography
- phase iii
- double blind
- phase ii
- coronary artery disease
- open label
- coronary artery
- acute coronary syndrome
- ejection fraction
- clinical trial
- end stage renal disease
- affordable care act
- quantum dots
- placebo controlled
- newly diagnosed
- angiotensin ii
- diabetic retinopathy
- randomized controlled trial
- aortic stenosis
- healthcare
- reduced graphene oxide
- prognostic factors
- peritoneal dialysis
- electronic health record
- big data
- machine learning
- visible light
- patient reported